New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging
Open Access
- 29 October 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10), e7628
- https://doi.org/10.1371/journal.pone.0007628
Abstract
Liposomal-based gadolinium (Gd) nanoparticles have elicited significant interest for use as blood pool and molecular magnetic resonance imaging (MRI) contrast agents. Previous generations of liposomal MR agents contained gadolinium-chelates either within the interior of liposomes (core-encapsulated gadolinium liposomes) or presented on the surface of liposomes (surface-conjugated gadolinium liposomes). We hypothesized that a liposomal agent that contained both core-encapsulated gadolinium and surface-conjugated gadolinium, defined herein as dual-mode gadolinium (Dual-Gd) liposomes, would result in a significant improvement in nanoparticle-based T1 relaxivity over the previous generations of liposomal agents. In this study, we have developed and tested, both in vitro and in vivo, such a dual-mode liposomal-based gadolinium contrast agent. Three types of liposomal agents were fabricated: core-encapsulated, surface-conjugated and dual-mode gadolinium liposomes. In vitro physico-chemical characterizations of the agents were performed to determine particle size and elemental composition. Gadolinium-based and nanoparticle-based T1 relaxivities of various agents were determined in bovine plasma. Subsequently, the agents were tested in vivo for contrast-enhanced magnetic resonance angiography (CE-MRA) studies. Characterization of the agents demonstrated the highest gadolinium atoms per nanoparticle for Dual-Gd liposomes. In vitro, surface-conjugated gadolinium liposomes demonstrated the highest T1 relaxivity on a gadolinium-basis. However, Dual-Gd liposomes demonstrated the highest T1 relaxivity on a nanoparticle-basis. In vivo, Dual-Gd liposomes resulted in the highest signal-to-noise ratio (SNR) and contrast-to-noise ratio in CE-MRA studies. The dual-mode gadolinium liposomal contrast agent demonstrated higher particle-based T1 relaxivity, both in vitro and in vivo, compared to either the core-encapsulated or the surface-conjugated liposomal agent. The dual-mode gadolinium liposomes could enable reduced particle dose for use in CE-MRA and increased contrast sensitivity for use in molecular imaging.This publication has 26 references indexed in Scilit:
- Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumorsBiomaterials, 2009
- Tumor Vascular Permeability to a Nanoprobe Correlates to Tumor-Specific Expression Levels of Angiogenic MarkersPLOS ONE, 2009
- T1 Relaxivity of Core-encapsulated Gadolinium Liposomal Contrast Agents—Effect of Liposome Size and Internal Gadolinium ConcentrationAcademic Radiology, 2008
- High relaxivity contrast agents in MR angiography of the carotid arteries.European Radiology Supplements, 2006
- A Liposomal System for Contrast-Enhanced Magnetic Resonance Imaging of Molecular TargetsBioconjugate Chemistry, 2004
- Controlled targeting of liposomal doxorubicin via the folate receptor in vitroJournal of Controlled Release, 2003
- Improved molecular imaging contrast agent for detection of human thrombusMagnetic Resonance in Medicine, 2003
- Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumineJournal of Magnetic Resonance Imaging, 2003
- Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imagingJournal of Magnetic Resonance Imaging, 2003
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003